Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSage Group Regulatory News (SGE)

Share Price Information for Sage Group (SGE)

Share Price is delayed by 15 minutes
Get Live Data
883.20    30.00 (3.52%)
Bid:
880.60
Ask:
881.40
Spread: 0.80 (0.091%)
Market Cap: £7.96b
SGE Live PriceLast checked at - London Stock Exchange

Intraday Sage Group Share Chart

SHARE BUYBACK PROGRAMME

15 May 2025 07:00

RNS Number : 7298I
Sage Group PLC (The)
15 May 2025
 

THE SAGE GROUP PLC

SHARE BUYBACK PROGRAMME

 

Sage announces that it is extending its ongoing share buyback programme by up to £200 million.

London 15 May 2025 - The Sage Group plc ("Sage" or the "Group") today announces a share buyback programme extension for aggregate consideration of up to £200 million (the "Extended Programme") which will commence on completion of its ongoing share buyback programme for aggregate consideration of up to £400 million announced on 20 November 2024 (the "Initial Programme").

The Initial Programme is expected to end no later than 3 June 2025 (as previously announced) and, following its completion, the Extended Programme will commence. The Extended Programme is expected to end no later than 6 August 2025.

The Extended Programme is consistent with the Group's disciplined capital allocation policy, and reflects the Board's confidence in Sage's future prospects, together with Sage's strong cash generation and robust financial position. Sage continues to have considerable financial flexibility to drive the execution of its growth strategy.

Further details of the Extended Programme are set out below.

________________________________________

Enquiries

The Sage Group plc: +44 (0) 7341 479956

Caroline Xu, Group Finance

James Sandford, Investor Relations

David Ginivan, Corporate PR

FGS Global: +44 (0) 20 7251 3801

Conor McClafferty

Sophia Johnston

________________________________________

Further details of the Extended Programme

Sage has entered into non-discretionary arrangements with Morgan Stanley & Co. International plc ("Morgan Stanley") and J.P. Morgan Securities plc ("J.P. Morgan") (together, the "Brokers") in relation to the purchase by the Brokers, acting as riskless principals, of ordinary shares of Sage (the "Shares"). Morgan Stanley will conduct the first half of the Extended Programme and J.P. Morgan will conduct the second half. The Extended Programme will commence on the trading day after the Initial Programme is completed and, in any case, no later than 4 June 2025.

The Brokers will make trading decisions in relation to Shares purchased under the Extended Programme independently of, and uninfluenced by, Sage. The purpose of the Extended Programme is to reduce the share capital of Sage. The Brokers will make an on-sale of such Shares to Sage and all Shares repurchased will be cancelled.

Any purchases of Shares contemplated by this announcement will be carried out on the London Stock Exchange and/or other recognised investment exchange(s) and will be effected within certain pre-set parameters. These arrangements are in accordance with Sage's general authority to repurchase Shares granted at its latest Annual General Meeting, Chapter 9 of the UK Listing Rules, and those provisions of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and the Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and with regard to regulatory technical standards for the conditions applicable to buyback programmes.

The maximum number of Shares which may currently be purchased or committed to be purchased by Sage under the Extended Programme is 81,555,354, which is the maximum number remaining as of the date of this announcement pursuant to the relevant authorities granted by shareholders at Sage's latest Annual General Meeting.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSFDFALEISEDI
Date   Source Headline
30th Jun 20239:48 amRNSDirector/PDMR Shareholding
27th Jun 20235:16 pmRNSDirector/PDMR Shareholding
21st Jun 20239:00 amRNSDirector/PDMR Shareholding
6th Jun 202312:02 pmRNSBlock listing Interim Review
31st May 20234:55 pmRNSHolding(s) in Company
31st May 20234:50 pmRNSTotal Voting Rights
30th May 202310:10 amRNSDirector/PDMR Shareholding
19th May 20234:58 pmRNSDirector/PDMR Shareholding
19th May 20234:45 pmRNSHolding(s) in Company
17th May 20237:00 amRNSResults for the six months to 31 March 2023
28th Apr 20233:30 pmRNSTotal Voting Rights
31st Mar 20232:11 pmRNSDirector/PDMR Shareholding
31st Mar 202312:40 pmRNSTotal Voting Rights
27th Mar 20231:40 pmRNSDirector/PDMR Shareholding
6th Mar 20234:42 pmRNSHolding(s) in Company
28th Feb 20231:50 pmRNSTotal Voting Rights
17th Feb 20235:22 pmRNSDirector/PDMR Shareholding
17th Feb 20235:02 pmRNSDirector/PDMR Shareholding
14th Feb 20233:59 pmRNSDirector/PDMR Shareholding
13th Feb 20236:16 pmRNSPublication of Final Terms
9th Feb 20239:32 amRNSDirector/PDMR Shareholding
7th Feb 20239:46 amRNSDirector/PDMR Shareholding
3rd Feb 202312:14 pmRNSDirector Declaration
2nd Feb 20233:31 pmRNSResult of AGM
2nd Feb 20239:57 amRNSDirector Declaration
31st Jan 20233:35 pmRNSSage: Publication of Base Prospectus
31st Jan 20233:00 pmRNSTotal Voting Rights
23rd Jan 20234:58 pmRNSDirector/PDMR Shareholding
19th Jan 20237:00 amRNSTrading Update for the 3 months ended 31 Dec 2022
30th Dec 202211:15 amRNSTotal Voting Rights
15th Dec 202211:21 amRNSDirector/PDMR Shareholding
8th Dec 20225:40 pmRNSDirector/PDMR Shareholding
8th Dec 20227:00 amRNSUpdate on financial reporting
7th Dec 20226:00 pmRNSDirector/PDMR Shareholding
7th Dec 202210:12 amRNSNotice of AGM
6th Dec 20226:13 pmRNSDirector/PDMR Shareholding
6th Dec 20225:23 pmRNSDirector/PDMR Shareholding
6th Dec 202210:25 amRNSBlock listing Interim Review
1st Dec 202211:03 amRNSAnnual Financial Report
30th Nov 20222:00 pmRNSTotal Voting Rights
24th Nov 202210:00 amRNSNon-executive Director Appointment
18th Nov 20229:13 amRNSDirector/PDMR Shareholding
16th Nov 20227:00 amRNSResults for the year ended 30 September 2022
15th Nov 20227:00 amRNSNon-executive Director Appointment
31st Oct 20223:00 pmRNSTotal Voting Rights
30th Sep 202211:45 amRNSTotal Voting Rights
20th Sep 20227:00 amRNSInvestor and Analyst Event
31st Aug 20223:44 pmRNSTotal Voting Rights
30th Aug 20225:10 pmRNSSage completes Lockstep acquisition
24th Aug 20223:37 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.